Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Terazosin Hydrochloride

FDA-approved product (tablet, oral), marketed as Hytrin, Terazosin Hydrochloride, Tezruly.

Registered studies
41
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Terazosin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Benign prostatic hyperplasia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Alpha-adrenoreceptor antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae40.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

41registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Terazosin Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Terazosin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Terazosin for Dementia With Lewy Bodies

    NCT04760860 · start 2027-10

    Registered record
    Registry ID
    NCT04760860
    Conditions
    Dementia With Lewy Bodies
    Interventions
    Terazosin Hydrochloride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2027-10
    Completion
    2030-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia With Lewy Bodies
    InterventionTerazosin Hydrochloride; Placebo
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • Terazosin And Metabolic Engagement in Alzheimer's Disease

    NCT07796308 · start 2027-08-01

    Registered record
    Registry ID
    NCT07796308
    Conditions
    Alzheimer s Disease
    Interventions
    Terazosin (Hytrin); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2027-08-01
    Completion
    2032-07-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer s Disease
    InterventionTerazosin (Hytrin); Placebo
    PhasePhase 2
    Registry statusNot yet recruiting

  • Terazosin And Metabolic Engagement in Parkinson's Disease

    NCT07288450 · start 2026-09-01

    Registered record
    Registry ID
    NCT07288450
    Conditions
    Parkinson's Disease
    Interventions
    Terazosin Hydrochloride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09-01
    Completion
    2031-09-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    InterventionTerazosin Hydrochloride; Placebo
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis

    NCT07224269 · start 2026-08-12

    Registered record
    Registry ID
    NCT07224269
    Conditions
    Amyotrophic Lateral Sclerosis; Adenosine Triphosphate Activities
    Interventions
    Terazosine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2026-08-12
    Completion
    2027-10-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyotrophic Lateral Sclerosis; Adenosine Triphosphate Activities
    InterventionTerazosine; Placebo
    PhaseEarly phase 1
    Registry statusRecruiting

  • Terazosin And Metabolic Energetics in Parkinson's Disease

    NCT07464028 · start 2026-07-01

    Registered record
    Registry ID
    NCT07464028
    Conditions
    Parkinson's Disease (PD)
    Interventions
    Terazosin 5 MG; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-07-01
    Completion
    2031-07-01
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease (PD)
    InterventionTerazosin 5 MG; Placebo
    PhasePhase 2
    Registry statusNot yet recruiting

  • Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial

    NCT07207057 · start 2025-09-12

    Registered record
    Registry ID
    NCT07207057
    Conditions
    Parkinsons Disease (PD)
    Interventions
    Placebo; Telmisartan; Terazosin (Hytrin)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-09-12
    Completion
    2031-07-31
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinsons Disease (PD)
    InterventionPlacebo; Telmisartan; Terazosin (Hytrin)
    PhasePhase 3
    Registry statusRecruiting

  • Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms

    NCT06966804 · start 2025-06-01

    Registered record
    Registry ID
    NCT06966804
    Conditions
    Stent Related Symptoms
    Interventions
    Terazosin; Tamsulosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-06-01
    Completion
    2027-07-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStent Related Symptoms
    InterventionTerazosin; Tamsulosin
    PhasePhase 3
    Registry statusRecruiting

  • Reduction of Edema With a Specialized Cocktail for Ultra-early Management in Intracerebral Hemorrhage

    NCT06863558 · start 2025-05-08

    Registered record
    Registry ID
    NCT06863558
    Conditions
    Intracerebral Hemorrhage
    Interventions
    PPA Intervention
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2025-05-08
    Completion
    2026-06-30
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntracerebral Hemorrhage
    InterventionPPA Intervention
    PhasePhase 3
    Registry statusNot yet recruiting

  • Reduction of Edema With a Specialized Cocktail for Ultra-early Management in Ischemic Stroke

    NCT06863571 · start 2025-04-12

    Registered record
    Registry ID
    NCT06863571
    Conditions
    Ischemic Stroke
    Interventions
    PPA Intervention
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-04-12
    Completion
    2026-06-30
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemic Stroke
    InterventionPPA Intervention
    PhasePhase 3
    Registry statusRecruiting

  • Motor Function Efficacy of Pharmacological Treatments Targeting Energy Metabolism, in Parkinson's Patients

    NCT05855577 · start 2023-12

    Registered record
    Registry ID
    NCT05855577
    Conditions
    Parkinson Disease; Gait Analysis; Therapy, Directly Observed; Metabolic Disease
    Interventions
    Terazosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-12
    Completion
    2026-05
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease; Gait Analysis; Therapy, Directly Observed; Metabolic Disease
    InterventionTerazosin
    PhasePhase 4
    Registry statusUnknown

  • Terazosin and Parkinson's Disease Extension Study

    NCT05109364 · start 2022-09-23

    Registered record
    Registry ID
    NCT05109364
    Conditions
    Symptomatic Parkinson Disease; REM Sleep Behavior Disorder; Pre-motor Parkinson's Disease
    Interventions
    Terazosin therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2022-09-23
    Completion
    2026-03-10
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSymptomatic Parkinson Disease; REM Sleep Behavior Disorder; Pre-motor Parkinson's Disease
    InterventionTerazosin therapy
    PhasePhase 2
    Registry statusActive not recruiting

  • Target Engagement of Terazosin in Healthy Adults

    NCT04551040 · start 2021-03-26

    Registered record
    Registry ID
    NCT04551040
    Conditions
    Healthy
    Interventions
    Terazosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2021-03-26
    Completion
    2025-06-30
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTerazosin
    PhasePhase 1
    Registry statusActive not recruiting

  • Terazosin Effect on Cardiac Changes in Early Parkinson's Disease

    NCT04386317 · start 2020-11-01

    Registered record
    Registry ID
    NCT04386317
    Conditions
    REM Sleep Behavior Disorder; Pre-motor Parkinson's Disease; Symptomatic Parkinson Disease
    Interventions
    Terazosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-11-01
    Completion
    2026-03-10
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionREM Sleep Behavior Disorder; Pre-motor Parkinson's Disease; Symptomatic Parkinson Disease
    InterventionTerazosin
    PhasePhase 2
    Registry statusActive not recruiting

  • Selective Versus Nonselective Alpha-blockade Prior to Pheochromocytoma Resection - Systematic Review and Meta-analysis

    NCT04557072 · start 2020-08-01

    Registered record
    Registry ID
    NCT04557072
    Conditions
    Pheochromocytoma
    Interventions
    Selective alpha-1-antagonist; Non-selective alpha-1-antagonist
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-08-01
    Completion
    2020-11-02
    Enrolment
    1,344

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPheochromocytoma
    InterventionSelective alpha-1-antagonist; Non-selective alpha-1-antagonist
    PhaseNot recorded
    Registry statusCompleted

  • ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

    NCT04467931 · start 2020-01-19

    Registered record
    Registry ID
    NCT04467931
    Conditions
    Hypertension; COVID
    Interventions
    ACEI/ARB; Non-ACEI/ARB; ACEI; ARB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-01-19
    Completion
    2020-12-31
    Enrolment
    22,213

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; COVID
    InterventionACEI/ARB; Non-ACEI/ARB; ACEI; ARB
    PhaseNot recorded
    Registry statusCompleted